This study was done in both Italy and the United States. A form of Vitamin A called fenretinide demonstrated protective effects against both breast and ovarian cancer. Looking at 2972 women ranging in age from 30 to 70 with early stage breast cancer or DCIS (ductal carcinoma insitu) took either oral fenretinide(200mgs) or a placebo, for five years. The study showed a significant reduction of ovarian cancer among women age 50 and younger (pre-menopausal). This group also benefited with reduction of second breast cancers. Dr. Michael Osborne, director of the Strang Cancer Prevention Center and chief of Breast Service at New York Presbyterian Hospital said the findings offer great promise for younger women in preventing breast cancer (ovarian too). Downside was some complaints of gastrointestinal problems and mucous dryness. Ann's NOTE: See the report under Ann's Bio-Ann's Protocol where I discuss my own successful use of Vitamin A. Too bad the STAR trial comparing tamoxifen and raloxifene doesn't include an arm for a Vitamin A group. Or any natural non-toxic or less toxic substance. Study, Nutrition, Nov-Dec, 2000 Study in JNCI May 2000 Study J Mammary Gland Biol Neoplasia October 1999 Phase II Study Oral Bexarotene:Mets Breast Cancer Res Treat, 11/02 Cancer Res, October 2007 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.